Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
McKesson
Baxter
Colorcon
Boehringer Ingelheim

Last Updated: August 15, 2022

Investigational Drug Information for BGB-A317


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for BGB-A317?

BGB-A317 is an investigational drug.

There have been 118 clinical trials for BGB-A317. The most recent clinical trial was a Phase 2 trial, which was initiated on May 29th 2020.

The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Carcinoma. The leading clinical trial sponsors are BeiGene, BeiGene USA, Inc., and Tianjin Medical University Second Hospital.

There are five US patents protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for BGB-A317
TitleSponsorPhase
Study of BGB-11417 in Participants With Leukemia or Lymphoma Who Failed or Were Intolerant To Prior Treatment With Bruton Tyrosine Kinase InhibitorsBeiGenePhase 2
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder CancerBeiGenePhase 2
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder CancerFirst Affiliated Hospital Xi'an Jiaotong UniversityPhase 2

See all BGB-A317 clinical trials

Clinical Trial Summary for BGB-A317

Top disease conditions for BGB-A317
Top clinical trial sponsors for BGB-A317

See all BGB-A317 clinical trials

US Patents for BGB-A317

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-A317 See Plans and Pricing Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment Bristol-Myers Squibb Company (Princeton, NJ) Celldex Therapeutics, Inc. (Hampton, NJ) See Plans and Pricing
BGB-A317 See Plans and Pricing Combination therapy with an anti-axl antibody-drug conjugate ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB) See Plans and Pricing
BGB-A317 See Plans and Pricing Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment Bristol-Myers Squibb Company (Princeton, NJ) Celldex Therapeutics, Inc. (Hampton, NJ) See Plans and Pricing
BGB-A317 See Plans and Pricing Anti-CD8 antibodies and uses thereof REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) See Plans and Pricing
BGB-A317 See Plans and Pricing Radiolabeled anti-LAG3 antibodies for immuno-PET imaging REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BGB-A317

Drugname Country Document Number Estimated Expiration Related US Patent
BGB-A317 Australia AU2018219909 2037-02-10 See Plans and Pricing
BGB-A317 Brazil BR112019016336 2037-02-10 See Plans and Pricing
BGB-A317 Canada CA3053348 2037-02-10 See Plans and Pricing
BGB-A317 Chile CL2019002264 2037-02-10 See Plans and Pricing
BGB-A317 China CN110650974 2037-02-10 See Plans and Pricing
BGB-A317 Colombia CO2019008675 2037-02-10 See Plans and Pricing
BGB-A317 Eurasian Patent Organization EA201991673 2037-02-10 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
McKesson
Baxter
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.